Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly : a randomized, open-label, multicentre study
Identifieur interne : 002964 ( PascalFrancis/Checkpoint ); précédent : 002963; suivant : 002965Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly : a randomized, open-label, multicentre study
Auteurs : Annamaria Colao [Italie] ; Paolo Cappabianca [Italie] ; Philippe Caron [France] ; Ernesto De Menis [Italie] ; Andrew J. Farrall [Royaume-Uni] ; Monica R. Gadelha [Brésil] ; Abdel Hmissi [Suisse] ; Aled Rees [Royaume-Uni] ; Martin Reincke [Allemagne] ; Mitra Safari [Suisse] ; Guy T'Sjoen [Belgique] ; Hakim Bouterfa [Suisse] ; Ross C. Cuneo [Australie]Source :
- Clinical endocrinology : (Oxford. Print)) [ 0300-0664 ] ; 2009.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Chirurgie, Homme, Médicament.
English descriptors
- KwdEn :
Abstract
Objective This prospective randomized study evaluated the efficacy and safety of octreotide LAR vs. surgery in newly diagnosed acromegalic patients. Methods Totally 104 male and female patients were enrolled in a 50-week, exploratory, open-label and randomized study. Eligible patients were randomized to receive either octreotide LAR 20 mg every 28 days or to undergo surgery. Efficacy was assessed by changes in mean GH and IGF-I serum concentrations, at weeks 12, 24 and 48. Tumour volume was assessed by contrast-enhanced MRI. In both groups, treatment adjustment was performed for patients uncontrolled at week 12 or 24. Octreotide LAR patients received a dose increased to 30 mg or, if already receiving this dose, investigator and patients could decide to cross-over to surgery. Patients uncontrolled after surgery received octreotide LAR 20 mg, increased to 30 mg if acromegaly was still uncontrolled. Results Overall success rates at weeks 24 and 48 were 25% and 28% for the octreotide LAR group and 49% and 39% for the surgery group. Only the difference observed at week 24 was statistically significant (P = 0-047). Both groups had a significant (> 20%) tumour shrinkage: 73% of patients in the octreotide LAR group and 95% in the surgery group. Major differences between octreotide LAR and surgery group in the occurrence of adverse events were gastrointestinal (71% vs. 27%), hepatobiliary (41% vs. 8%) and respiratory (5% vs. 28%). Conclusion This first randomized study in unselected patients indicates that the 48-week treatment outcome of octreotide LAR as first-line treatment of acromegaly does not significantly differ from surgery. As a complete response to surgery in GH-secreting macro-adenomas can be difficult, first-line therapy with octreotide LAR can be considered as a viable alternative for most patients with acromegaly, due to its low complication rate.
Affiliations:
- Allemagne, Australie, Belgique, Brésil, France, Italie, Royaume-Uni, Suisse
- Bavière, District de Haute-Bavière, Midi-Pyrénées, Occitanie (région administrative), Écosse, État de Rio de Janeiro
- Munich, Rio de Janeiro, Toulouse, Édimbourg
- Université Louis-et-Maximilien de Munich, Université d'Édimbourg
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:09-0164227Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly : a randomized, open-label, multicentre study</title><author><name sortKey="Colao, Annamaria" sort="Colao, Annamaria" uniqKey="Colao A" first="Annamaria" last="Colao">Annamaria Colao</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples</s1><s2>Naples</s2><s3>ITA</s3><sZ>1 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Cappabianca, Paolo" sort="Cappabianca, Paolo" uniqKey="Cappabianca P" first="Paolo" last="Cappabianca">Paolo Cappabianca</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurological Sciences, Section of Neurosurgery, Federico II University of Naples</s1><s2>Naples</s2><s3>ITA</s3><sZ>2 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Caron, Philippe" sort="Caron, Philippe" uniqKey="Caron P" first="Philippe" last="Caron">Philippe Caron</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>CHU de Rangueil-Larrey</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="De Menis, Ernesto" sort="De Menis, Ernesto" uniqKey="De Menis E" first="Ernesto" last="De Menis">Ernesto De Menis</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Ospedale Generale Ca'Foncello</s1><s2>Treviso</s2><s3>ITA</s3><sZ>4 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Ospedale Generale Ca'Foncello</wicri:noRegion></affiliation></author><author><name sortKey="Farrall, Andrew J" sort="Farrall, Andrew J" uniqKey="Farrall A" first="Andrew J." last="Farrall">Andrew J. Farrall</name><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>University of Edinburgh</s1><s2>Edinburgh</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region><settlement type="city">Édimbourg</settlement></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation></author><author><name sortKey="Gadelha, Monica R" sort="Gadelha, Monica R" uniqKey="Gadelha M" first="Monica R." last="Gadelha">Monica R. Gadelha</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Hospital Universitdrio Clementino Fraga Filho (UFRJ)</s1><s2>Rio de Janeiro</s2><s3>BRA</s3><sZ>6 aut.</sZ></inist:fA14><country>Brésil</country><placeName><settlement type="city">Rio de Janeiro</settlement><region type="state">État de Rio de Janeiro</region></placeName></affiliation></author><author><name sortKey="Hmissi, Abdel" sort="Hmissi, Abdel" uniqKey="Hmissi A" first="Abdel" last="Hmissi">Abdel Hmissi</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Novartis Pharma AG</s1><s2>Basel</s2><s3>CHE</s3><sZ>7 aut.</sZ><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Novartis Pharma AG</wicri:noRegion></affiliation></author><author><name sortKey="Rees, Aled" sort="Rees, Aled" uniqKey="Rees A" first="Aled" last="Rees">Aled Rees</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Centre for Endocrine and Diabetes Sciences, Cardiff University</s1><s2>Cardiff</s2><s3>GBR</s3><sZ>8 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Cardiff</wicri:noRegion></affiliation></author><author><name sortKey="Reincke, Martin" sort="Reincke, Martin" uniqKey="Reincke M" first="Martin" last="Reincke">Martin Reincke</name><affiliation wicri:level="4"><inist:fA14 i1="09"><s1>Klinikum der Universität München</s1><s2>Munich</s2><s3>DEU</s3><sZ>9 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Safari, Mitra" sort="Safari, Mitra" uniqKey="Safari M" first="Mitra" last="Safari">Mitra Safari</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Novartis Pharma AG</s1><s2>Basel</s2><s3>CHE</s3><sZ>7 aut.</sZ><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Novartis Pharma AG</wicri:noRegion></affiliation></author><author><name sortKey="T Sjoen, Guy" sort="T Sjoen, Guy" uniqKey="T Sjoen G" first="Guy" last="T'Sjoen">Guy T'Sjoen</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>University Hospital</s1><s2>Gent</s2><s3>BEL</s3><sZ>11 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Bouterfa, Hakim" sort="Bouterfa, Hakim" uniqKey="Bouterfa H" first="Hakim" last="Bouterfa">Hakim Bouterfa</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Novartis Pharma AG</s1><s2>Basel</s2><s3>CHE</s3><sZ>7 aut.</sZ><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Novartis Pharma AG</wicri:noRegion></affiliation></author><author><name sortKey="Cuneo, Ross C" sort="Cuneo, Ross C" uniqKey="Cuneo R" first="Ross C." last="Cuneo">Ross C. Cuneo</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Metabolic Research Unit, Princess Alexandra Hospital, University of Queensland</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>13 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0164227</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0164227 INIST</idno><idno type="RBID">Pascal:09-0164227</idno><idno type="wicri:Area/PascalFrancis/Corpus">002E86</idno><idno type="wicri:Area/PascalFrancis/Curation">003134</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002964</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002964</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly : a randomized, open-label, multicentre study</title><author><name sortKey="Colao, Annamaria" sort="Colao, Annamaria" uniqKey="Colao A" first="Annamaria" last="Colao">Annamaria Colao</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples</s1><s2>Naples</s2><s3>ITA</s3><sZ>1 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Cappabianca, Paolo" sort="Cappabianca, Paolo" uniqKey="Cappabianca P" first="Paolo" last="Cappabianca">Paolo Cappabianca</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurological Sciences, Section of Neurosurgery, Federico II University of Naples</s1><s2>Naples</s2><s3>ITA</s3><sZ>2 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Caron, Philippe" sort="Caron, Philippe" uniqKey="Caron P" first="Philippe" last="Caron">Philippe Caron</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>CHU de Rangueil-Larrey</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="De Menis, Ernesto" sort="De Menis, Ernesto" uniqKey="De Menis E" first="Ernesto" last="De Menis">Ernesto De Menis</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Ospedale Generale Ca'Foncello</s1><s2>Treviso</s2><s3>ITA</s3><sZ>4 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Ospedale Generale Ca'Foncello</wicri:noRegion></affiliation></author><author><name sortKey="Farrall, Andrew J" sort="Farrall, Andrew J" uniqKey="Farrall A" first="Andrew J." last="Farrall">Andrew J. Farrall</name><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>University of Edinburgh</s1><s2>Edinburgh</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region><settlement type="city">Édimbourg</settlement></placeName><orgName type="university">Université d'Édimbourg</orgName></affiliation></author><author><name sortKey="Gadelha, Monica R" sort="Gadelha, Monica R" uniqKey="Gadelha M" first="Monica R." last="Gadelha">Monica R. Gadelha</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Hospital Universitdrio Clementino Fraga Filho (UFRJ)</s1><s2>Rio de Janeiro</s2><s3>BRA</s3><sZ>6 aut.</sZ></inist:fA14><country>Brésil</country><placeName><settlement type="city">Rio de Janeiro</settlement><region type="state">État de Rio de Janeiro</region></placeName></affiliation></author><author><name sortKey="Hmissi, Abdel" sort="Hmissi, Abdel" uniqKey="Hmissi A" first="Abdel" last="Hmissi">Abdel Hmissi</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Novartis Pharma AG</s1><s2>Basel</s2><s3>CHE</s3><sZ>7 aut.</sZ><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Novartis Pharma AG</wicri:noRegion></affiliation></author><author><name sortKey="Rees, Aled" sort="Rees, Aled" uniqKey="Rees A" first="Aled" last="Rees">Aled Rees</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Centre for Endocrine and Diabetes Sciences, Cardiff University</s1><s2>Cardiff</s2><s3>GBR</s3><sZ>8 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Cardiff</wicri:noRegion></affiliation></author><author><name sortKey="Reincke, Martin" sort="Reincke, Martin" uniqKey="Reincke M" first="Martin" last="Reincke">Martin Reincke</name><affiliation wicri:level="4"><inist:fA14 i1="09"><s1>Klinikum der Universität München</s1><s2>Munich</s2><s3>DEU</s3><sZ>9 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement><settlement type="city">Munich</settlement></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author><author><name sortKey="Safari, Mitra" sort="Safari, Mitra" uniqKey="Safari M" first="Mitra" last="Safari">Mitra Safari</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Novartis Pharma AG</s1><s2>Basel</s2><s3>CHE</s3><sZ>7 aut.</sZ><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Novartis Pharma AG</wicri:noRegion></affiliation></author><author><name sortKey="T Sjoen, Guy" sort="T Sjoen, Guy" uniqKey="T Sjoen G" first="Guy" last="T'Sjoen">Guy T'Sjoen</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>University Hospital</s1><s2>Gent</s2><s3>BEL</s3><sZ>11 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Bouterfa, Hakim" sort="Bouterfa, Hakim" uniqKey="Bouterfa H" first="Hakim" last="Bouterfa">Hakim Bouterfa</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Novartis Pharma AG</s1><s2>Basel</s2><s3>CHE</s3><sZ>7 aut.</sZ><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Novartis Pharma AG</wicri:noRegion></affiliation></author><author><name sortKey="Cuneo, Ross C" sort="Cuneo, Ross C" uniqKey="Cuneo R" first="Ross C." last="Cuneo">Ross C. Cuneo</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Metabolic Research Unit, Princess Alexandra Hospital, University of Queensland</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>13 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Clinical endocrinology : (Oxford. Print))</title><title level="j" type="abbreviated">Clin. endocrinol. : (Oxf., Print)</title><idno type="ISSN">0300-0664</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Clinical endocrinology : (Oxford. Print))</title><title level="j" type="abbreviated">Clin. endocrinol. : (Oxf., Print)</title><idno type="ISSN">0300-0664</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acromegaly</term><term>Clinical trial</term><term>Comparative study</term><term>Drug</term><term>Early stage</term><term>Endocrinology</term><term>Human</term><term>Multicenter study</term><term>Octreotide</term><term>Patient</term><term>Randomization</term><term>Surgery</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Octréotide</term><term>Etude comparative</term><term>Stade précoce</term><term>Chirurgie</term><term>Homme</term><term>Malade</term><term>Acromégalie</term><term>Randomisation</term><term>Essai clinique</term><term>Médicament</term><term>Etude multicentrique</term><term>Endocrinologie</term><term>Traitement</term><term>Essai thérapeutique</term><term>Essai ouvert</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Chirurgie</term><term>Homme</term><term>Médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective This prospective randomized study evaluated the efficacy and safety of octreotide LAR vs. surgery in newly diagnosed acromegalic patients. Methods Totally 104 male and female patients were enrolled in a 50-week, exploratory, open-label and randomized study. Eligible patients were randomized to receive either octreotide LAR 20 mg every 28 days or to undergo surgery. Efficacy was assessed by changes in mean GH and IGF-I serum concentrations, at weeks 12, 24 and 48. Tumour volume was assessed by contrast-enhanced MRI. In both groups, treatment adjustment was performed for patients uncontrolled at week 12 or 24. Octreotide LAR patients received a dose increased to 30 mg or, if already receiving this dose, investigator and patients could decide to cross-over to surgery. Patients uncontrolled after surgery received octreotide LAR 20 mg, increased to 30 mg if acromegaly was still uncontrolled. Results Overall success rates at weeks 24 and 48 were 25% and 28% for the octreotide LAR group and 49% and 39% for the surgery group. Only the difference observed at week 24 was statistically significant (P = 0-047). Both groups had a significant (> 20%) tumour shrinkage: 73% of patients in the octreotide LAR group and 95% in the surgery group. Major differences between octreotide LAR and surgery group in the occurrence of adverse events were gastrointestinal (71% vs. 27%), hepatobiliary (41% vs. 8%) and respiratory (5% vs. 28%). Conclusion This first randomized study in unselected patients indicates that the 48-week treatment outcome of octreotide LAR as first-line treatment of acromegaly does not significantly differ from surgery. As a complete response to surgery in GH-secreting macro-adenomas can be difficult, first-line therapy with octreotide LAR can be considered as a viable alternative for most patients with acromegaly, due to its low complication rate.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0300-0664</s0></fA01><fA02 i1="01"><s0>CLECAP</s0></fA02><fA03 i2="1"><s0>Clin. endocrinol. : (Oxf., Print)</s0></fA03><fA05><s2>70</s2></fA05><fA06><s2>5</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly : a randomized, open-label, multicentre study</s1></fA08><fA11 i1="01" i2="1"><s1>COLAO (Annamaria)</s1></fA11><fA11 i1="02" i2="1"><s1>CAPPABIANCA (Paolo)</s1></fA11><fA11 i1="03" i2="1"><s1>CARON (Philippe)</s1></fA11><fA11 i1="04" i2="1"><s1>DE MENIS (Ernesto)</s1></fA11><fA11 i1="05" i2="1"><s1>FARRALL (Andrew J.)</s1></fA11><fA11 i1="06" i2="1"><s1>GADELHA (Monica R.)</s1></fA11><fA11 i1="07" i2="1"><s1>HMISSI (Abdel)</s1></fA11><fA11 i1="08" i2="1"><s1>REES (Aled)</s1></fA11><fA11 i1="09" i2="1"><s1>REINCKE (Martin)</s1></fA11><fA11 i1="10" i2="1"><s1>SAFARI (Mitra)</s1></fA11><fA11 i1="11" i2="1"><s1>T'SJOEN (Guy)</s1></fA11><fA11 i1="12" i2="1"><s1>BOUTERFA (Hakim)</s1></fA11><fA11 i1="13" i2="1"><s1>CUNEO (Ross C.)</s1></fA11><fA14 i1="01"><s1>Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples</s1><s2>Naples</s2><s3>ITA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Neurological Sciences, Section of Neurosurgery, Federico II University of Naples</s1><s2>Naples</s2><s3>ITA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>CHU de Rangueil-Larrey</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Ospedale Generale Ca'Foncello</s1><s2>Treviso</s2><s3>ITA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>University of Edinburgh</s1><s2>Edinburgh</s2><s3>GBR</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Hospital Universitdrio Clementino Fraga Filho (UFRJ)</s1><s2>Rio de Janeiro</s2><s3>BRA</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>Novartis Pharma AG</s1><s2>Basel</s2><s3>CHE</s3><sZ>7 aut.</sZ><sZ>10 aut.</sZ><sZ>12 aut.</sZ></fA14><fA14 i1="08"><s1>Centre for Endocrine and Diabetes Sciences, Cardiff University</s1><s2>Cardiff</s2><s3>GBR</s3><sZ>8 aut.</sZ></fA14><fA14 i1="09"><s1>Klinikum der Universität München</s1><s2>Munich</s2><s3>DEU</s3><sZ>9 aut.</sZ></fA14><fA14 i1="10"><s1>University Hospital</s1><s2>Gent</s2><s3>BEL</s3><sZ>11 aut.</sZ></fA14><fA14 i1="11"><s1>Metabolic Research Unit, Princess Alexandra Hospital, University of Queensland</s1><s2>Brisbane</s2><s3>AUS</s3><sZ>13 aut.</sZ></fA14><fA20><s1>757-768</s1></fA20><fA21><s1>2009</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>15568</s2><s5>354000187432460150</s5></fA43><fA44><s0>0000</s0><s1>© 2009 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>36 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>09-0164227</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Clinical endocrinology : (Oxford. Print))</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Objective This prospective randomized study evaluated the efficacy and safety of octreotide LAR vs. surgery in newly diagnosed acromegalic patients. Methods Totally 104 male and female patients were enrolled in a 50-week, exploratory, open-label and randomized study. Eligible patients were randomized to receive either octreotide LAR 20 mg every 28 days or to undergo surgery. Efficacy was assessed by changes in mean GH and IGF-I serum concentrations, at weeks 12, 24 and 48. Tumour volume was assessed by contrast-enhanced MRI. In both groups, treatment adjustment was performed for patients uncontrolled at week 12 or 24. Octreotide LAR patients received a dose increased to 30 mg or, if already receiving this dose, investigator and patients could decide to cross-over to surgery. Patients uncontrolled after surgery received octreotide LAR 20 mg, increased to 30 mg if acromegaly was still uncontrolled. Results Overall success rates at weeks 24 and 48 were 25% and 28% for the octreotide LAR group and 49% and 39% for the surgery group. Only the difference observed at week 24 was statistically significant (P = 0-047). Both groups had a significant (> 20%) tumour shrinkage: 73% of patients in the octreotide LAR group and 95% in the surgery group. Major differences between octreotide LAR and surgery group in the occurrence of adverse events were gastrointestinal (71% vs. 27%), hepatobiliary (41% vs. 8%) and respiratory (5% vs. 28%). Conclusion This first randomized study in unselected patients indicates that the 48-week treatment outcome of octreotide LAR as first-line treatment of acromegaly does not significantly differ from surgery. As a complete response to surgery in GH-secreting macro-adenomas can be difficult, first-line therapy with octreotide LAR can be considered as a viable alternative for most patients with acromegaly, due to its low complication rate.</s0></fC01><fC02 i1="01" i2="X"><s0>002A28</s0></fC02><fC02 i1="02" i2="X"><s0>002B21A01</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Octréotide</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Octreotide</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Octreotida</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Etude comparative</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Comparative study</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Estudio comparativo</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Stade précoce</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Early stage</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Estadio precoz</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Chirurgie</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Surgery</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Cirugía</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Human</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Malade</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Patient</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Enfermo</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Acromégalie</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Acromegaly</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Acromegalia</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Randomisation</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Randomization</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Aleatorización</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Essai clinique</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Clinical trial</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Ensayo clínico</s0><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Médicament</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Drug</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Medicamento</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Etude multicentrique</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Multicenter study</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Estudio multicéntrico</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Endocrinologie</s0><s5>17</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Endocrinology</s0><s5>17</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Endocrinología</s0><s5>17</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Traitement</s0><s5>25</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Treatment</s0><s5>25</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Tratamiento</s0><s5>25</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Essai thérapeutique</s0><s4>INC</s4><s5>86</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Essai ouvert</s0><s4>INC</s4><s5>87</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Analogue</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Analog</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Análogo</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Somatostatine</s0><s2>NK</s2><s2>FR</s2><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Somatostatin</s0><s2>NK</s2><s2>FR</s2><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Somatostatina</s0><s2>NK</s2><s2>FR</s2><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Endocrinopathie</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Endocrinopathy</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Endocrinopatía</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'hypophyse</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Pituitary diseases</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Hipófisis patología</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du système ostéoarticulaire</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Diseases of the osteoarticular system</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Sistema osteoarticular patología</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Hormone peptide</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Peptide hormone</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Hormona péptido</s0><s5>42</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Neuropeptide</s0><s5>43</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Neuropeptide</s0><s5>43</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Neuropéptido</s0><s5>43</s5></fC07><fN21><s1>117</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>Brésil</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>Suisse</li></country><region><li>Bavière</li><li>District de Haute-Bavière</li><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li><li>Écosse</li><li>État de Rio de Janeiro</li></region><settlement><li>Munich</li><li>Rio de Janeiro</li><li>Toulouse</li><li>Édimbourg</li></settlement><orgName><li>Université Louis-et-Maximilien de Munich</li><li>Université d'Édimbourg</li></orgName></list><tree><country name="Italie"><noRegion><name sortKey="Colao, Annamaria" sort="Colao, Annamaria" uniqKey="Colao A" first="Annamaria" last="Colao">Annamaria Colao</name></noRegion><name sortKey="Cappabianca, Paolo" sort="Cappabianca, Paolo" uniqKey="Cappabianca P" first="Paolo" last="Cappabianca">Paolo Cappabianca</name><name sortKey="De Menis, Ernesto" sort="De Menis, Ernesto" uniqKey="De Menis E" first="Ernesto" last="De Menis">Ernesto De Menis</name></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Caron, Philippe" sort="Caron, Philippe" uniqKey="Caron P" first="Philippe" last="Caron">Philippe Caron</name></region></country><country name="Royaume-Uni"><region name="Écosse"><name sortKey="Farrall, Andrew J" sort="Farrall, Andrew J" uniqKey="Farrall A" first="Andrew J." last="Farrall">Andrew J. Farrall</name></region><name sortKey="Rees, Aled" sort="Rees, Aled" uniqKey="Rees A" first="Aled" last="Rees">Aled Rees</name></country><country name="Brésil"><region name="État de Rio de Janeiro"><name sortKey="Gadelha, Monica R" sort="Gadelha, Monica R" uniqKey="Gadelha M" first="Monica R." last="Gadelha">Monica R. Gadelha</name></region></country><country name="Suisse"><noRegion><name sortKey="Hmissi, Abdel" sort="Hmissi, Abdel" uniqKey="Hmissi A" first="Abdel" last="Hmissi">Abdel Hmissi</name></noRegion><name sortKey="Bouterfa, Hakim" sort="Bouterfa, Hakim" uniqKey="Bouterfa H" first="Hakim" last="Bouterfa">Hakim Bouterfa</name><name sortKey="Safari, Mitra" sort="Safari, Mitra" uniqKey="Safari M" first="Mitra" last="Safari">Mitra Safari</name></country><country name="Allemagne"><region name="Bavière"><name sortKey="Reincke, Martin" sort="Reincke, Martin" uniqKey="Reincke M" first="Martin" last="Reincke">Martin Reincke</name></region></country><country name="Belgique"><noRegion><name sortKey="T Sjoen, Guy" sort="T Sjoen, Guy" uniqKey="T Sjoen G" first="Guy" last="T'Sjoen">Guy T'Sjoen</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Cuneo, Ross C" sort="Cuneo, Ross C" uniqKey="Cuneo R" first="Ross C." last="Cuneo">Ross C. Cuneo</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002964 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 002964 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:09-0164227
|texte= Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly : a randomized, open-label, multicentre study
}}
| This area was generated with Dilib version V0.6.33. |  |